Alcon AG is expected to report Q1 2026 revenue of $2.70 billion and consensus earnings per share of $0.83, with the stock currently trading at $63.50 relative to an average analyst price target of $94.50.
Investors are primarily focused on the commercial traction and adoption rates of the Unity surgical platform, which is expected to catalyze a significant equipment replacement cycle. Analysts are also looking for sustained market share gains in the premium Advanced Technology Intraocular Lens (ATIOL) category to offset competitive pricing pressures in international markets. Execution in these high-margin segments remains critical for the company to achieve its projected core operating margin expansion of up to 170 basis points for the full year.